Regulators Work On Global Biosimilar Extrapolation Rules, MAb Assessments
This article was originally published in SRA
Executive Summary
As part of its regulatory convergence effort, the International Pharmaceutical Regulators Forum is working on two projects intended to help align global requirements regarding the extrapolation of indications for biosimilar medicines and the assessment of biosimilar monoclonal antibodies (MAbs).
You may also be interested in...
How To Extrapolate For Biosimilars: New Guidance From International Regulators’ Forum
The international regulators’ forum, the IPRF, has produced guidance on the issues associated with extrapolation that national regulatory bodies should take into consideration when evaluating biosimilar medicines submitted for approval.
How To Extrapolate For Biosimilars: New Guidance From International Regulators’ Forum
The international regulators’ forum, the IPRF, has produced guidance on the issues associated with extrapolation that national regulatory bodies should take into consideration when evaluating biosimilar medicines submitted for approval.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.